Introduction
For centuries, the genetic composition of domestic animals has been manipulated to enhance their usefulness to humans. In the past decade, development of recombinant DNA technology has enabled scientists to isolate single genes, analyze and modify their nucleotide structures, make copies of these isolated genes, and transfer copies into the genome. An animal that integrates recombinant DNA in its genome is called "transgenic," and the transferred gene is called a "transgene."
Recently, medically important human proteins have been produced in large quantities in milk of transgenic sheep. Unless unforeseen complications arise during extraction and purification of these proteins, we can expect to see such products being clinically evaluated soon. Use of transgenic animals for food and fiber remains in the future. Few agriculturally useful genes have thus far been isolated, sequenced, and cloned. In addition, knowledge of gene regulation is currently insufficient. As a consequence, integrated transgenes are insufficiently controlled, resulting in overexpression that adversely affects the health status of transgenics with elevated growth hormone ( GH) and may limit the usefulness of other structural transgenes.
The purpose of this paper is to review the progress that has been achieved since transgenic modification of swine and sheep was first reported in 1985 (Hammer et al., 1985b) , with emphasis on developments in mammals during the past few years.
Methods of Transferring Genes
Microinjection of Pronuclei. The predominant method used to transfer cloned genes into animals is direct microinjection into the pronuclei of fertilized eggs. Although microinjection of mouse pronuclei is readily performed, direct application to other species was impeded by the opacity of the egg cytoplasm. Pronuclei of rabbit, sheep, and goat eggs can be readily seen using differential interference contrast (DIC) microscopy. However, pig and cow eggs must be centrifuged to induce stratification of the cytoplasm before the pronuclei are visible with use of DIC microscopy (Wall et al., 1985) .
The mechanism by which injected DNA integrates into a chromosome is unknown. Frequently, injected DNA results in multiple copies of the gene integrating either in head-to-tail or head-to-head array. Usually the DNA integrates in a single site, but multiple integrations can occur (Wilkie et al., 1986; . About 70% of transgenic mice produced by microinjection carry the transgene in all cells, and the remaining 30% are mosaic, presumably due to integration of the gene at a relatively late cleavage stage after microinjection (Wilkie et al., 1986) . Breeding studies with pigs and sheep indicate that mosaicism is a definite problem; about 20% of founder transgenics fail to transmit the gene to progeny and another 20 to 30% transmit the transgene to less than 50%, presumably due to mosaicism in the germ cells (Purse1 et al., 1990b) .
After microinjection, cow eggs are usually cultured in vitro until they are morulae or blastocysts before nonsurgical transfer into the uterus of a synchronous host cow. The injected eggs of the other species are usually cultured only a few hours before they are transferred directly into the oviduct of synchronous host females. Pig ova can be transferred into the oviducts of donor females immediately after the ova have been recovered without compromising the pregnancy rate or subsequent litter size (Pursel and Wall, 1989) .
The efficiency of gene integration into the genome tends to be lower for farm animals than for mice. The percentage of gene-injected embryos that develop into transgenic animals varied from .31 to 4.03% for pigs, .1 to 4.45% for sheep, and .34 to 2.63% for cattle. The overall efficiencies are remarkably similar for farm animals ( Table 1) . Some of the important parameters that influence the frequency of integration have been described for mice but have not been systematically investigated in other species.
Retroviral Insertion. Retroviruses can be modified by recombinant DNA techniques and then used as gene vectors. Infection of embryos with retrovirus has been successful in several species (Jaenisch, 1976; Petters et al., 1987; Salter et al., 1987) . Retroviral infection receives considerable attention because it offers several advantages over microinjection in certain applications. Its principal advantages are 1) integration of single copies of the gene without rearrangement at the site of integration and 2 ) retroviral DNA integrates into a high percentage of embryos that can be infected by exposure to high concentrations of viral stock, by co-culture with infected cells in vitro, or, in the case of chickens, by microinjection into the blastodisk. The disadvantages are 1) added work to produce a retrovirus carrying the transgene, 2 ) a size limit on the gene to be inserted into the retrovirus, 3 ) a high incidence of mosaicism in resulting transgenics necessitates extensive outbreeding to establish pure transgenic lines, and 4 ) unresolved problems with expression of the transgene (Jaenisch, 1988) .
The use of retroviral vectors to insert genes into birds has received much more attention than its use in mammals, because by the time an egg is laid, it has about 60,000 cells in the blastoderm, so microinjection with DNA is not feasible. Both replication-competent and replication-defective retroviral vectors have been used to transfer genes into chickens (for reviews, see Bosselman et al., 1990 and Crittenden, 1991) . However, the fear of a defective vector reverting to an infective state inhibits greater use of retroviral vectors.
Stem Cell Insertion. The third method of introducing genes into the germ line involves transfer of a gene into embryonic stem (ES) cells in culture and then incorporating these transgenic ES cells into an embryo, which is then chimeric for the transgene. The advantage of this procedure is that a particular genotype can be selected in vitro before introduction of the ES cells into the embryo. In addition, this technique is the only one that provides the ability for site-specific insertion of a transgene by homologous recombination (Capecchi, 1989) . A major disadvantage of this procedure at present is that many of the chimeric transgenic mice do not contain the transgene in their germ cells. Thus far, only transgenic mice have been produced by this method, but several laboratories are attempting to develop embryonic stem cells for each of the livestock species.
Sperm as Vector. Recently, transgenic mice and pigs were produced by in vitro incubation of DNA and spermatozoa together and subsequent use of the spermatozoa for in vitro fertilization or oviductal insemination (Gandolfi et al., 1989) . Unfortunately, these results have not yet been repeated by the many laboratories that have tried .
Improved Productivity Traits
Transfer of genes for improved animal productivity traits, such as feed conversion, rate of gain, reduction of fat, and improved quality of meat, milk, or wool, would have a dramatic impact on the livestock industry and reduce the cost of animal products for the consumer. These productivity traits are controlled by numerous genes, of which only a few are presently known. The expansion of research on mapping the genomes of livestock species should be helpful in elucidating more of the economically important genes.
Growth Hormone. Numerous GH transgenes have been transferred into livestock species ( Table 2 ) . Most of the pigs and lambs that expressed these transgenes had continuously elevated GH in their plasma. The concentration of GH varied greatly among transgenics with the same structural gene, which is thought to be the result of random insertion of transgenes into the genome. In general, pigs and lambs did not grow larger than their siblings. Some pigs gained weight faster, were 17% more efficient in converting feed into meat, and at market weight contained only one-fifih as much carcass fat as littermates (Figure 1 ; Pursel et al., 1990b) . A marked reduction in lipid was also observed in the intramuscular tissue of each of the primal cuts in comparison to sibling controls ( Figure  2) . Transgenic lambs did not grow faster or utilize feed more efficiently than control lambs, but they were much leaner (Rexroad et al., 1989 Nancarrow et al., 1991) . In transgenic lambs, the lack of body fat may have been the result of hyperglycemia and glycosuria (Rexroad et al., 1989 . Transgenic lambs with elevated GH also had a number of other pathologies, including joint problems and degenerative kidney disease . Transgenic pigs with continuously elevated GH had a high incidence of joint pathology, gastric ulcers, and infertility (Pursel et al., 1987 (Pursel et al., , 1989b Ebert et al., 1988 Ebert et al., , 1990 Wieghart et al., 1990) . In transgenic mice, both MT and PEPCK regulatory sequences could be manipulated by dietary changes to modify expression of GH transgenes (Palmiter et al., 1983; McGrane et al., 1988) , but these regulatory sequences were much less responsive to dietary manipulation in transgenic pigs and sheep Pursel et al., 1990a; Wieghart et al,, 1990 ). Fully regulatable GH transgenes could provide positive effects of elevated GH during the latter portion of the growth period and avoid most of the deleterious health problems. Evidence to support this suggestion has recently been reported by Pomp et al. (1992) and Shanahan et al. (1989) , using an ovine MT-oGH fusion gene in mice. The oGH transgenic mice had normal GH levels until 25 mM zinc sulfate was added to their water to induce oGH expression. These mice then responded by growing to 1.4 times the body weight of their nontransgenic siblings. When zinc was removed from their drinking water, the GH levels returned to basal levels within 24 h; the mice were able to reproduce, and deleterious effects on health were avoided (Shanahan et al., 1989) . In the future, such a high degree of regulated transgene expression should be possible for farm animals. Several laboratories are continuing to conduct research on this problem because of the obvious economic gain that producers and consumers would accrue because of the improvement in feed efficiency and reduction in fat.
Growth Hormone-Releasing Factor. Transgenic pigs and sheep have been produced using MT and ALB promoter/regulatory sequences. Only two of seven (29%) pigs and one of seven (14%) lambs expressed the MT-human growth hormone-releasing factor (hGRF) transgene (Rexroad et al., 1989; Pursel et al., 1990b) . In contrast, 11 of 14 (79%) transgenic mice expressed MT-hGRF (Hammer et al., 1985a) . Reasons for this discrepancy in incidence of expression among species are unknown, but possibly particular combinations of promotor/structural sequences are less effective in some species than in others. In contrast, all three pigs and two of four lambs expressed the ALB-hGRF transgene.
The concentration of GRF in plasma of transgenic pigs with MT-hGRF or ALB-hGRF were 130 t o 380 pg/ mL and 400 to 8,000 pg/mL, respectively (Pursel et al., 1989a,b) . These values are 10-to 500-fold higher than concentrations of GRF in plasma of littermate control pigs (Table 3 1. However, most of the assayable GRF in plasma of the MT-hGRF pigs was the 3-44 metabolite rather than the native peptide (1-44), which may explain why the concentration of pGH in plasma was not elevated in the transgenics compared to the littermate controls (Pursel et al., 1989a) . In contrast, the transgenic lambs had elevated GH in response to the hGRF transgenes, and, as a consequence, the lambs were phenotypically similar to the bGH and oGH transgenic lambs.
Insulin-Like Growth Factor I. Four transgenic pigs (Pursel et al., 1989b) and seven transgenic calves have been produced with insulin-like growth factor I (IGF-I) transgenes (Hill et al., 1992) . However, only one of the pigs expressed elevated levels of IGF-I and it died before growth performance could be evaluated. No information has been published regarding expression or performance of the transgenic calves.
Stimulation of Muscle Development. Sutrave et al. (1990) reported that mice expressing a chicken OSKI transgene exhibited a distinct phenotype characterized by hypertrophy of skeletal muscles and reduced body fat. The gene transferred into mice consisted of a mouse sarcoma virus ( MSV) LTR promoter fused to a truncated cSKl cDNA. The transgene product is a protein containing 448 amino acids that is localized primarily in muscle nuclei. The normal function of cSKI and its mode of action is unknown.
The MSV-cSKI gene has now been transferred into the genome of swine . Preliminary results indicate that expression of the cSKI transgene in swine resulted in a wide range of phenotypes among animals. Five transgenic pigs exhibited varying degrees of muscular hypertrophy that was visually detected at approximately 3 mo of age. In three pigs, both hams and shoulders appeared enlarged, and in two pigs, hypertrophy was evident only in the shoulders. Levels of gene expression in muscles of these pigs have not yet been determined. In contrast, between birth and 3 mo of age, five other OSKI transgenic pigs exhibited muscular atonia and weakness in both the front and rear legs. Skeletal muscles from these pigs had high levels of cSKI mRNA, and bGH transgenic pigs at 80 to 100 kg body weight (Pursel et al., 1990b) .
cSKl transgenic pigs will be made with progeny of these founders when they become available.
Wool Production. Cysteine is the rate-limiting amino acid for the production of wool. Addition of cysteine to the diet does not increase wool production because the rumen degrades it. Bacterial genes are capable of fixing sulfur into cysteine; thus, the transgenic approach might be used to introduce the bacterial enzymes into sheep to improve the growth of wool (Ward et al., 1990) . Two laboratories in Australia are making rapid progress on producing transgenic sheep with the bacterial genes for serine transacetylase and o-acetylserine sulfhydrylase, which have been isolated and characterized for Escherichia coli and Salmonella typhirnuriurn (Rogers, 1990) . Ward and Nancarrow (1991) have succeeded in transferring these genes into mice and obtained high levels of active enzyme in the intestine. Rogers and coworkers (Rogers, 1990) have transferred the bacterial genes into both mice and sheep. Neither group has thus far shown that these transgenic animals can synthesize cysteine. Figure 2 . The mean percentages of intramuscular fat are shown for primal cuts of four control and four bovine growth hormone (bGH) transgenic sibling pigs at 90 to 98 kg body weight at harvest (P < .01) (Solomon and Pursel, 1991) .
PRIMAL CUT

Improved Animal Health
Application of transgenic technology holds considerable promise for improved animal health in the future. Several approaches under investigation include transfer of genes for naturally occurring disease resistance, for preformed antibodies, and for viral coat proteins. When immunologists have a fuller understanding of the major histocompatibility complex, these genes may be extremely useful for enhancing disease resistance.
Naturally Occum'ng Disease Resistance. Mice carrying the autosomal dominant Mxl allele are resistant to influenza virus. This gene has been cloned and characterized (Staeheli et al., 1986) . Interferon stimulates M x protein production, which promotes resistance to viral infection (Muller and Brem, 1991) . Brem (1993) transferred three M x fusion genes ( Table 2 ) into swine to test their effectiveness. Two of five transgenic pigs harboring the M x regulatory and structural sequences were found to respond to interferon induction of M x mRNA. However, the response was insufficient to produce detectable amounts of M x protein in the tissues. The other two fusion genes that were transferred into pigs were rearranged during integration, so they were not functional.
Preformed Antibodies. Genes encoding mouse Q heavy and K light chains from antibodies against phosphorylcholine ( PC) were co-injected into ova to produce two transgenic pigs and three transgenic lambs (Lo et al., 1991) . In the transgenic pigs, the mouse immunoglobulin A ( IgA) was detected in the serum despite the failure of an intact mouse K transgene to integrate. Transgenic progeny from both founders demonstrated high levels of serum mouse IgA starting a t approximately 5 wk of age. Average levels of mouse IgA were 630 pg/mL in one line and 1,293 pg/mL in the other. In both cases, IgA levels in progeny were higher than those in the founders. However, mouse IgA showed little binding specificity for PC, presumably because secreted chimeric antibody included endogenous light chains with mouse heavy chains. In transgenic sheep, mouse IgA was detectable in peripheral lymphocytes but not in serum.
These studies need to be expanded to obtain conclusive proof that the IgA transgene would be protective against pathogenic bacteria.
In a similar study, Weidle et al. (1991) produced two transgenic pigs and three transgenic rabbits that harbored mouse X heavy and K light chain transgenes from antibodies directed against the hapten 4-hydroxy-3-nitrophenylacetate ( NP) . Titers of 100 to 300 pg of IgG/mL in transgenic rabbits and up to 1,000 pg of IgG/mL in one transgenic pig were present in the serum of founders and transgenic progeny. Further evaluation of the antibody composition indicated that xenogeneic antibodies had formed by association of light chains of rabbit and pig with heavy chains of the mouse.
It is clear from these recent studies that further investigations should consider using homologous regulatory sequences t o inhibit formation of chimeric antibodies with low binding specificity for the target antigen.
Enhanced Disease Resistance. Visna virus, a lentivirus, is widely present in the sheep population (Narayan, 1974) . In the United States, ovine progress pneumonia (OPP) is the disease commonly associated with this retrovirus. Ovine progress pneumonia is common in older ewes and greatly reduces their productivity. One transgenic approach for production of resistance to retroviral infection is introduction of defective retrovirus. In chickens, defective retrovirus that coded for the envelope protein produced resistance to retroviral infection (Crittenden and Salter, 1990) . In our studies, a gene construct was formed by ligation of the sheep visna virus LTR to the coding sequence for envelope protein of visna virus. Three transgenic lambs were produced by microinjection of the gene construct into a pronucleus of single-cell sheep embryos ( 0 . Narayan, J. Clements, R. Wall, and C. Rexroad, personal communication) . The transgene was found to be present and functional in populations of macrophages (the usual target cell) and skin fibroblasts from all three lambs. A functional protein was present, as indicated by the fusogenic properties of some fibroblasts in culture. The protection level afforded by the presence of an envelope protein already present in target cells has not yet been evaluated. The presence and function of the envelope protein under the direction of the LTR suggests that the approach may be valid if protection results from interaction of membrane viral receptors and envelope protein.
Bioreactors for Rare Medical Products
Transgenic livestock may soon play an important role in providing new life-saving medical products for treating a variety of human diseases. This is certainly not a new role for farm animals. Thousands of people have in the past benefited from biomedical products derived from farm animals. Notable examples include replacement heart valves, insulin to treat diabetes, and oxytocin to induce labor during childbirth.
The most significant recent advance in gene transfer involves the direction of expression of considerable quantities of foreign protein to the mammary glands of livestock. A key factor responsible for this high level of transgene expression is the use of genomic DNA for the structural gene instead of cDNA, which had been used previously (Wright et al., 1991) . These findings fully support the earlier research of Brinster et al. (1988) in mice that showed that inclusion of introns in gene constructs usually resulted in higher levels of transgene expression than when the same regulatory sequences were ligated to cDNA.
The promotodregulatory sequences that have been investigated for their potential t o direct expression of foreign proteins to the mammary gland include sheep &lactoglobulin ( BLG) ; cow a-S1-casein; rabbit, rat, and cow &casein; and mouse whey acidic protein (WAP) ( Table 2) . Because the casein proteins constitute the majority of the protein in milk, one might expect casein promotorhegulatory sequences to be the most effective for transgenes. So far, this assumption has been incorrect, possibly because several casein genes are clustered together, which may make their regulation more complex than that of single genes.
The regulatory sequences that prove to be most effective for directing high levels of pharmaceutical should also prove to be useful for modifying milk composition for agricultural purposes, and vice versa. Several of these non-pharmaceutical purposes include reduction of mastitis, alteration of casein composition for production of cheese or for production of human proteins in milk of farm animals to provide human infants with a better substitute for a mother's breast milk, alternation of lactose composition, and reduction or alteration in butterfat content (Jimenez-Flores and Richardson, 1988; Bremel et al., 1989; Wilmut et al. 1990 ).
Whey Acidic Protein. Recently, the mouse WAP gene was transferred into swine and sheep to test whether this gene, which is normally only found in rodent species, might be effective for expressing transgenes in the mammary glands of livestock . Milk has been evaluated from six lines of transgenic pigs and two transgenic sheep. Mouse WAP made up about 3% of the total milk proteins in the transgenic sows and ewes, thus demonstrating that it is possible to produce high levels of a foreign protein in milk of pigs and sheep.
Quite unexpectedly, five sows from three lines of WAP transgenic pigs produced milk only a few days before becoming agalactic . Lactation failure was not accompanied by elevated body temperature, lack of maternal behavior, loss of appetite, or by other symptoms that normally accompany agalactia in swine. Neither mice nor sheep expressing other mammary-specific transgenes have previously exhibited this phenomenon. Recent data from mice and pigs indicate that in agalactic females the transgene starts producing WAP early in gestation rather than late in gestation, as is common in rodents. This early expression in some way interferes with normal mammary development and causes early involution (Shamay et al., 1992 ; R. J. Wall and L. Hennighausen, personal communication) .
Human Protein C. Velander et al. (1992) inserted cDNA of human protein C ( hPC) into the first exon of the WAP gene to produce several transgenic pigs. Lactating transgenic sows produced up to 1 g of hPC per liter of milk. The biological activity of the recombinant hPC was equivalent to that of protein C derived from human plasma, which makes it commercially feasible to extract hPC from milk, purify it, and clinically evaluate its efficacy and safety.
Protein C plays an important role in the regulation of hemostasis. When sufficient quantities are availa- Tissue Plasminogen Activator. The mouse WAP promotor/regulator has also been used to express a variant of human tissue plasminogen activator (hTPA) cDNA in a transgenic goat (Ebert et al., 1991) . Tissue plasminogen activator (TPA) is an anti-clotting agent currentIy used to treat patients immediately after they suffer a heart attack. Only low concentrations of hTPA were found in the milk, and expression of the hTPA had no adverse effect on milk production or general health of this transgenic goat. However, when another transgenic goat was produced with the &casein promotor instead of the WAP promotor, a much higher level of hTPA was produced. This goat became agalactic soon after parturition. Whether the agalactia was the result of expression of hTPA or was just a characteristic of this particular goat remains to be determined by additional experi-
Human Alpha-l-Antitrypsin. Wright et al. (1991) recently reported that high levels of human alphal-antitrypsin ( h q A T ) expression in milk have been obtained in four transgenic ewes in which sheep BLG regulatory sequences were ligated to h q A T genomic sequences. The concentration of h q A T at the 7th wk of lactation varied from 1.5 to 37.5 g/L among the ewes, and, most remarkably, halAT made up more than half the protein contained in the milk from one transgenic ewe (Wright et al., 1991) . In spite of the extraordinarily high levels of halAT production, the ewes had normal durations of lactation and exhibited no ill effects from the transgene. The high level of transgene expression with genomic h q A T sharply contrasted with earlier investigations in which only low levels of expression were obtained when BLG had been Iigated to cDNA of halAT (Wilmut et al., 19901 or human Factor IX (Clark et al., 1989) .
The glycosylation and biological activity of halAT purified from transgenic sheep milk seemed to be indistinguishable from that of h q A T purified from human plasma (Wright et al., 1991) . Whether the sugar composition of the carbohydrate side-chains has been altered remains to be determined.
Human alpha-l-antitrypsin is being investigated for its potential to treat the more than 20,000 people in the United States who are afflicted with a common hereditary deficiency in halAT that predisposes them to life-threatening emphysema. Currently, halAT is extracted from human blood plasma, but the large quantity needed per patient (about 200 g per year) makes that source inadequate and expensive. Currently, a year's supply of h q A T costs about $22,000 per patient.
Human Lactofenin. Krimpenfort et al. (199 1) have succeeded in producing two transgenic calves that integrated a fusion gene composed of bovine aS1-casein promotor/regulator and human lactoferrin (hLF) coding sequences. The crS1-casein portion of the transgene was composed of 15 kbp of 5'-flanking and 6 kbp of 3'-flanking sequences, which contain elements that have previously confirmed tissuespecific expression in transgenic mice (Meade et al., 1990) . Unfortunately, the transgene was only detected in the placental tissue in the heifer calf, so it is unlikely that she will transmit the gene to progeny or produce hLF when she lactates. It will be several years before the progeny of the transgenic bull calf can be tested for the presence of hLF in milk.
Human Hemoglobin. Hemoglobin is one of several biomedical proteins that cannot be synthesized by the mammary gland but could be produced in other organs of transgenic animals and recovered from the blood. In crisis treatment, in the field, free hemoglobin would be superior to whole blood or concentrated red blood cells for transfusions because free hemoglobin does not require refrigeration. Hemoglobin would be particularly useful on the battlefield and for major natural disasters because, unlike red blood cells, it lacks antigenic components. Thus, hemoglobin would be compatible with all blood types.
Scientists at the DNX Corporation, Princeton, N J have recently reported producing three transgenic pigs that harbor the human a-and @-globin genes (Swanson et al., 1992) . In these transgenic pigs, about 15% of the red blood cells are producing human hemoglobin instead of pig hemoglobin. The hemoglobin is extracted from the red blood cells, and the human and pig hemoglobin are then separated by ion exchange chromatography. The purified hemoglobin must then be chemically modified so that the protein chains are crosslinked or polymerized. This chemical alternation is critical; otherwise, the globin chains would be unstable and incapable of releasing oxygen to the tissues when used for a transfusion. Previous clinical trials with chemical modification of human hemoglobin that had been extracted from human donor blood cells proved to be unsuccessful. Thus, scientists at DNX do not expect the human hemoglobin produced from these particular transgenic pigs to be useful for transfusion. Information gained from studying them will be extremely useful for designing subsequent experiments. The next step is to alter human globin genes in such a way that the globin genes are crosslinked and have reduced oxygen affinity. A number of research laboratories have research in progress on this complex problem.
Problems Remain
Even though several human therapeutical proteins have now been successfully produced in milk and blood of transgenic animals, some difficult problems must be solved before these products are approved for use. Product safety is a large issue. These products will require the same rigorous scrutiny as the products extracted from animal tissue, produced by tissue culture or synthesized by recombinant organisms.
Products from transgenic animals must be purified to remove all non-human proteins that might cause allergic reactions. In addition, it is still not known whether these complex human proteins are sufficiently similar in structure and biological activity to the natural proteins produced by the human body so that antibodies are not produced. Although scientists are confident that these technical and regulatory obstacles can be overcome, few people are willing to predict how long it will take to work out these problems and complete the clinical testing that will be required to obtain FDA approval for marketing.
Conclusions
Although efficiencies in transferring genes remain low and the list of genes that are worthy candidates for enhancing the productivity of farm animals is short, achievements during the past few years should encourage expansion of research on genetic engineering. The success in directing high levels of transgene expression to the mammary gland should stimulate considerable activity on pharmaceuticals for human patients and on modification of milk composition. In addition, the need for greater understanding of gene regulation should stimulate additional research in that important area. Although transgenic farm animals with enhanced performance for farm use still remain only a hope for the future, we think recent progress toward achieving this goal is evident. After all, humans have improved farm animals via selection since time immemorial without knowing what specific genes were being selected. Why, then, should we expect that in a 10-yr period we would know how t o efficiently improve farm animals just because we know how to introduce a few single genes out of the tens of thousands that are present in an animal?
Literature Cited
